Amylyx Pharma to remove ALS drug from US, Canada markets

April 4 (Reuters) – Amylyx Pharmaceuticals (AMLX.O) will withdraw its amyotrophic lateral sclerosis (ALS) drug – its only product in the market – from the U.S. and Canada after the treatment failed in a key late-stage trial.
 
The drugmaker on Thursday also announced a 70% reduction in its workforce. It had 384 full-time employees at the end of 2023.
 
WHY IT’S IMPORTANT:
The ALS drug, branded Relyvrio, was approved in 2022 after lobbying by patient groups who pointed to limited options to treat the potentially fatal disease.
 
/by
You might also like
FDAFDA’s top drug approvals of 2022
Future of Amylyx’s ALS drug in question after Phase III failure
Reata shares hit 1-year high after surprise FDA nod for rare disease drug
FDA signNeurofilament biomarker to face key test at Biogen-Ionis’ Tofersen Adcomm
FDAFDA approved 37 novel drugs in 2022
FDAReutersFDA staff reviewers raise concerns over BrainStorm Cell’s ALS therapy
Stacy Lindborg, Brainstorm Cell TherapeuticsBrainStorm’s ALS drug heads to the FDA with correction to Phase III analyses
Stacy Lindborg, Brainstorm Cell TherapeuticsAmylyx sheds more light on Relyvrio’s late-stage trial failure in ALS